Overview
On 28 June 2019, orphan designation EU/3/19/2168 was granted by the European Commission to Khondrion B.V., the Netherlands, for (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidine-3-yl)chroman-2-carboxamide hydrochloride (also known as KH176) for the treatment of maternally inherited diabetes and deafness.
Key facts
Active substance |
(S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidine-3-yl)chroman-2-carboxamide hydrochloride
|
Intended use |
Treatment of maternally-inherited diabetes and deafness
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/19/2168
|
Date of designation |
28/06/2019
|
Sponsor |
Khondrion BV |
Update history
Date | Update |
---|---|
March 2023 | The sponsor's address was updated. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: